What patents cover Evrysdi (risdiplam), and who owns them?
Evrysdi (risdiplam) is a small-molecule drug for spinal muscular atrophy (SMA). Patents covering risdiplam typically include composition-of-matter claims (the drug itself) and related inventions such as specific formulations and uses for SMA. Ownership and which specific patent family covers which claim set depend on the country and the patent filing/grant history.
When does the Evrysdi patent expire?
Patent expiry for medicines like Evrysdi depends on the patent’s jurisdiction, its filing date, and whether any patent term adjustments or extensions apply. Without specific patent numbers and countries, the exact expiry date can’t be stated accurately from the general term “Evrysdi patent.” Many drug makers also have multiple overlapping patent families, so exclusivity can end in stages rather than on a single date.
Can generics or biosimilars enter before Evrysdi’s patents expire?
For small-molecule drugs like risdiplam, the next competitive challenge is usually generic versions rather than biosimilars. Generics generally cannot be marketed until relevant patents and regulatory exclusivity barriers expire or are overcome (for example, via patent challenge outcomes or license arrangements). The practical timeline also depends on regulatory approvals in each country.
Are there patent challenges or “skinny label” / launch strategies for Evrysdi?
Patent disputes often focus on whether a competitor’s manufacturing or proposed product would infringe specific claims, and whether those claims are valid. Launch strategies can also include timing a launch around “first allowable” regulatory and patent dates, which can differ from the latest-expiring patent in the same family.
What should you look up to find the exact Evrysdi patent expiry date?
To get an accurate expiry date, search for:
- The risdiplam (Evrysdi) patent family in the relevant jurisdiction(s) (e.g., US, EP/UK, JP).
- The specific patent numbers and their grant statuses.
- Regulatory exclusivity periods tied to approval in that country (these are separate from patents).
If you tell me the country (US, EU, UK, Japan, etc.) and whether you mean “patent expiry” or “market exclusivity,” I can narrow down what to check and how to interpret the dates.
Which Evrysdi-related terms are often confused with “patent”?
People sometimes mix up:
- Patent expiry (legal rights from specific patents).
- Regulatory exclusivity (rules that prevent certain approvals/marketing for a period).
- Data exclusivity vs. market exclusivity (distinct protections).
These can differ, so a drug’s “can competitors sell it?” date may not match the “latest patent expiry” date.
Sources
No sources were provided in the prompt, so I did not cite any information.